Acid Addition Salt of Dihydropyridine Derivative

Abstract

There is provided an excellent medicine for treating or preventing hypertension or the like. A specific acid addition salt of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is useful as a medicine for treating or preventing hypertension or the like.

1 . An acid addition salt of a dihydropyridine compound which comprises a hydrobromide, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate or naphthalenesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       2 . The acid addition salt of the compound according to  claim 1 , wherein the compound is a hydrobromide, methanesulfonate or p-toluenesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       3 . The acid addition salt of the compound according to  claim 2 , wherein the compound is a hydrobromide of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       4 . The acid addition salt of the compound according to  claim 3 , wherein the compound is a dihydrobromide of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       5 . A crystal of The acid addition salt of the compound according to  claim 4 , wherein the dihydrobromide of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is in a form of a crystal. 
   
   
       6 . The acid addition salt of the compound according to  claim 5 , wherein the compound in the crystal form shows main d spacing peaks at 16, 4.4, 3.9, 3.1 and 3.0 Å in a powder X-ray diffraction pattern obtained by irradiation with Cu Kα rays. 
   
   
       7 . The acid addition salt of the compound according to  claim 2 , wherein the compound is a methanesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       8 . The acid addition salt of the compound according to  claim 7 , wherein the compound is a dimethanesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       9 . The acid addition salt of the compound according to  claim 8 , wherein the dimethanesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is in a form of a crystal. 
   
   
       10 . The acid addition salt of the compound according to  claim 9 , wherein the compound in the crystal form shows main d spacing peaks at 12, 7.8, 6.1, 4.8 and 4.5 Å in a powder X-ray diffraction pattern obtained by irradiation with Cu Kα rays. 
   
   
       11 . The acid addition salt of the compound according to  claim 7 , wherein the compound is a trimethanesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       12 . The acid addition salt of the compound according to  claim 11 , wherein the trimethanesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is in a form of a crystal. 
   
   
       13 . The acid addition salt of the compound according to  claim 12 , wherein the compound in the crystal form shows main d spacing peaks at 11, 4.6, 4.4, 3.9 and 3.6 Å in a powder X-ray diffraction pattern obtained by irradiation with Cu Kα rays. 
   
   
       14 . The acid addition salt of the compound according to  claim 2 , wherein the compound is a p-toluenesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       15 . The acid addition salt of the compound according to  claim 14 , wherein the compound is a di-p-toluenesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester. 
   
   
       16 . The acid addition salt of the compound according to  claim 15 , wherein the di-p-toluenesulfonate of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is in a form of a crystal. 
   
   
       17 . The acid addition salt of the compound according to  claim 16 , wherein the compound in the crystal form shows main d spacing peaks at 6.8, 4.9, 4.7 and 4.2 Å in a powder X-ray diffraction pattern obtained by irradiation with Cu Kα rays. 
   
   
       18 . A pharmaceutical composition for treating or preventing hypertension, heart disease, arteriosclerosis or nephropathy, the pharmaceutical composition comprising the salt compound according to  claim 1  as an active ingredient and a pharmaceutically acceptable carrier. 
   
   
       19 . The pharmaceutical composition according to  claim 18  for treating or preventing hypertension. 
   
   
       20 . (canceled) 
   
   
       21 . (canceled) 
   
   
       22 . A method for treating or preventing hypertension, heart disease, arteriosclerosis or nephropathy, the method comprising administering a pharmacologically effective amount of the salt compound according to  claim 1  to a warm-blooded animal. 
   
   
       23 . The method according to  claim 22  for treating or preventing hypertension. 
   
   
       24 . The method according to  claim 22 , wherein the warm-blooded animal is a human.